Novartis Access

Harald Nusser, Global Head Novartis Access

Bangkok, Asia Development Bank, January, 2016

Novartis Access

www.novartisaccess.com

Ida Marie PantigStamp

Noncommunicable diseases disproportionally affect low- and middle-income countries

Sources: WHO Fact Sheet noncommunicable diseases, January 2015

Noncommunicable diseases prematurely take 16 million lives annually, WHO urges more action, January 2015

28m deaths every year in low- and

middle-income countries (LMICs)

82% of NCD deaths

in LMICs are caused by

CARDIOVASCULAR

DISEASES

CANCERS

RESPIRATORY

DISEASES

DIABETES

accounting for

nearly 75% of global NCD deaths

80%

of the global disease burden will be due to NCDs

by 2020

1 | Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only

The Novartis mission

Discovering new ways

to extend and improve peoples lives


We believe Corporate Responsibility must be closely linked to our business strategy

To deliver

better

patient

outcomes

Science-

based

innovation

In

growing

areas of

healthcare

KAE609 Coartem DT

Education Affordable

medicines

Developing markets


Innovation doesnt just mean new drugs we must also innovate to improve access

Innovate business

model to

improve access

Address unmet

medical need with

new drugs

Innovation


We dont have all the answers but we have an approach

Commercial

for profit

High Income

Poverty

Low Income

Middle Income

High Middle Income

Economic objective

Social objective

Income Segments

Social Business

Not-for-profit

Philanthropy


Our contribution: Novartis Access

6

OUR AIM

TO HELP REVERSE THE TIDE OF NCDs

BY ENABLING GOVERNMENTS in low and lower middle income countries

TO PROVIDE BETTER CARE

FOR PATIENTS

| Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only

Novartis Access: Innovating our business model in low and lower middle income countries

7

DRIVE AVAILABILITY

AND AFFORTABILITY OF

HIGH-QUALITY MEDICINES

ENSURE

STANDARD OF CARE

Targeting four main chronic diseases

and breast cancer

Collaboration with governments and NGOs to ensure

patients are properly diagnosed and treated

CARDIOVASCULAR

DISEASES

BREAST

CANCER

RESPIRATORY

DISEASES

DIABETES

DIAGNOSIS TREATMENT

A portfolio of 15 medicines for governments, NGOs and other institutional customers

at USD 1 per treatment per month


CARDIOVASCULAR

DISEASES

Hypertension

Dyslipidemia

Heart failure

DIABETES

BREAST CANCER

RESPIRATORY

DISEASES

Chronic Obstructive Pulmonary Disease

Asthma

A portfolio of NCD medicines selected to meet the greatest health needs

8

Significant health need Addressing top 7 causes of death in low and lower middle income countries

Medical relevance Offering most commonly used dosage form and products that are either:

On or belonging to a class included in the WHO Model List of Essential Medicines

Belong to the most frequently prescribed medicines in these disease areas

Lack of access programs Expanding access to medicine where only few programs currently exist


30 countries identified for highest impact

9

30 COUNTRIES

Considered to be low- and low-

middle-income countries by:

Lack of access-to-medicine programs

and disproportionate impact

Essential set-up to make a launch

feasible

Local teams and partners on the

ground to support Novartis Access

High unmet NCD needs

Healthcare infrastructure

and/or NGO partnerships

Strong Novartis

presence

107 countries in

Access to Medicine index


Collaborations are key to Novartis Access from consultation to implementation

10

Trusted partners in academia, scientific communities

and NGOs contribute throughout the development, launch

and implementation process:

First idea New social business model

Need Field expertise and impact projections

Portfolio Medical feedback on dosage form and essential medicines

Countries Greatest needs and impact, healthcare infrastructure

Partnerships Definition of common operating model

Implementation Adaptation of operating model

Learning for expansion


Implementing Novartis Access on the ground main points for collaborations

Integrity of the distribution chain

Capacity building (screening, diagnosis, referral mechanisms, dosing and patient compliance to treatment)

Measurement of social impact (awareness, treatment availability and affordability)


Novartis Access: Five Year Vision

Sustainable business approach

Proven impact

Trusted partnerships

12

Sustainable business approach

Proven impact

Trusted partnerships


www.novartisaccess.com

Novartis Access

Documents

Transcript of Novartis Access